Monitor upcoming topline data from the C-BEYOND trial in mid-2026 as a key catalyst; assess potential for BEM/RZR to become a best-in-class HCV regimen. Watch cash runway given current burn rate and no near-term revenue.
Price Chart
Executive Summary
Atea Pharmaceuticals reported financial results for Q4 and full year 2025, showing increased R&D spend due to its Phase 3 HCV program and a cash balance of $301.8 million. The company highlighted progress in its HCV regimen (BEM/RZR), with topline Phase 3 data expected mid-2026 (C-BEYOND) and year-end 2026 (C-FORWARD), and announced plans to initiate clinical development of AT-587 for HEV in mid-2026. Despite higher net losses, the sentiment is mixed due to advancing late-stage programs offset by declining cash and no revenue generation.
Key Financial Metrics
Key Facts
- Cash and investments decreased from $454.7M (Dec 2024) to $301.8M (Dec 2025).
- R&D expenses increased to $148.0M in 2025 from $144.1M in 2024, driven by HCV Phase 3 trials and a Merck milestone payment.
- Net loss for 2025 was $158.3M vs. $168.4M in 2024; EPS improved to -$1.94 from -$2.00.
- Topline data from HCV Phase 3 C-BEYOND trial expected mid-2026; C-FORWARD results anticipated by year-end 2026.
- AT-587, a lead HEV candidate, is set to enter clinical development in mid-2026.
Financial Impact
Cash burn of $152.9 million in 2025 with increasing R&D investment; net loss narrowed slightly despite higher R&D.
Risk Factors
- High cash burn could necessitate future dilutive financing.
- Clinical trial delays or negative topline results could significantly impact valuation.
- No approved products or revenue; entirely dependent on development-stage candidates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250663 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | SC 13G | $5.01 | awaiting T+60 | — | $4.16 (−16.97%) |
Jul 14, 2026 14w ago | Press Release | $4.70 $5.01 | ▲ +6.60% | ▲ +3.22% | $4.16 (−11.49%) |
May 12, 2026 23w ago | Press Release | $4.57 $5.25 | ▼ −14.88% | ▼ −10.44% | $4.16 (+8.97%) |
Apr 27, 2026 26w ago | DEFA14A | $5.58 $4.75 | ▼ −14.87% | ▼ −18.86% | $4.16 (−25.45%) |
Mar 5, 2026 33w ago | 8-K | $5.89 $4.38 | ▼ −25.64% | ▼ −38.42% | $4.16 (−29.37%) |
Mar 5, 2026 33w ago | Press Release | $5.89 $4.38 | ▼ −25.64% | ▼ −38.42% | $4.16 (−29.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers